[{"address1": "1895 Mount Hope Avenue", "city": "Rochester", "state": "NY", "zip": "14620", "country": "United States", "phone": "585 271 2700", "fax": "585 271 2765", "website": "https://www.vaccinex.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Dr. Maurice  Zauderer Ph.D.", "age": 77, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1946, "fiscalYear": 2023, "totalPay": 411702, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elizabeth E. Evans Ph.D.", "age": 50, "title": "COO and Senior VP of Discovery & Translational Medicine", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 291569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ernest S. Smith Ph.D.", "age": 51, "title": "Senior VP of Research & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 297255, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jill  Sanchez CPA", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John E. Leonard Ph.D.", "age": 76, "title": "Senior Vice President of Development", "yearBorn": 1947, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.13, "open": 5.19, "dayLow": 5.035, "dayHigh": 5.498, "regularMarketPreviousClose": 5.13, "regularMarketOpen": 5.19, "regularMarketDayLow": 5.035, "regularMarketDayHigh": 5.498, "beta": 0.916, "forwardPE": -38.428574, "volume": 11009, "regularMarketVolume": 11009, "averageVolume": 87698, "averageVolume10days": 38120, "averageDailyVolume10Day": 38120, "marketCap": 9295026, "fiftyTwoWeekLow": 4.21, "fiftyTwoWeekHigh": 52.5, "priceToSalesTrailing12Months": 26.109623, "fiftyDayAverage": 6.1006, "twoHundredDayAverage": 7.6593, "currency": "USD", "enterpriseValue": 10563026, "floatShares": 478763, "sharesOutstanding": 1727700, "sharesShort": 43931, "sharesShortPriorMonth": 18804, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0277, "heldPercentInsiders": 0.0634, "heldPercentInstitutions": 0.64917, "shortRatio": 0.33, "shortPercentOfFloat": 0.0531, "bookValue": -2.677, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -17757000, "trailingEps": -3.96, "forwardEps": -0.14, "enterpriseToRevenue": 29.671, "enterpriseToEbitda": -0.491, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VCNX", "underlyingSymbol": "VCNX", "shortName": "Vaccinex, Inc.", "longName": "Vaccinex, Inc.", "firstTradeDateEpochUtc": 1533821400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "85e0d108-d5e4-34e8-828a-44192c187037", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.38, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "totalCash": 233000, "totalCashPerShare": 0.135, "ebitda": -21507000, "totalDebt": 122000, "quickRatio": 0.244, "currentRatio": 0.421, "totalRevenue": 356000, "revenuePerShare": 0.318, "returnOnAssets": -4.95644, "freeCashflow": -12235250, "operatingCashflow": -15734000, "operatingMargins": -24.66379, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-26"}]